Steris Plc SEC Filings

STERIS plc filed a Form 144 reporting a proposed sale of 159 ordinary shares through Charles Schwab & Co., Inc. on 10/06/2025 with an aggregate market value of $38,449. The securities were acquired on 10/01/2025 by lapse of restricted stock granted as equity compensation. The filing lists 98,490,606 shares outstanding, so the 159 shares represent an immaterial fraction of the company's outstanding stock. No other sales in the past three months are reported and the filer affirms they are not aware of undisclosed material adverse information.

John Adam Zangerle, Senior Vice President, General Counsel and Secretary of STERIS plc (STE), reported that 202 restricted ordinary shares awarded on October 1, 2021 vested on October 1, 2025. Of those vested shares, 91 were withheld to satisfy tax withholding obligations, recorded as a disposition. After the transaction, Mr. Zangerle beneficially owns 33,669 ordinary shares. The filing notes 8,511 ordinary shares remain restricted with staggered lapse dates between June 1, 2026 and June 5, 2028. The Form 4 was signed by an authorized representative on October 3, 2025.

STERIS plc (STE) reporting person Cary L. Majors, identified as SVP and President, Healthcare, reported transactions dated 10/01/2025. 692 ordinary shares vested that day from an award granted on 10/01/2021; 303 of those shares were withheld to satisfy required taxes, with a reported price of $0 for the withholding entry. After the transaction, the report shows 13,427 ordinary shares beneficially owned (direct) and 67 share equivalents held in the STERIS Corporation 401(k) Plan (indirect) as of 10/02/2025. The filing notes 10,138 ordinary shares remain restricted with scheduled lapses between 06/01/2026 and 06/05/2028. The form is signed by an authorized representative on 10/03/2025.

Daniel A. Carestio, who serves as President and CEO and a Director of STERIS plc (STE), reported a Section 16 transaction dated 10/01/2025. On that date 289 restricted ordinary shares that had been awarded on 10/01/2021 vested and 130 of those vested shares were withheld to satisfy tax withholding obligations, leaving the reporting person with 51,255 ordinary shares beneficially owned following the transaction. The filing states that 33,054 ordinary shares remain restricted with scheduled lapse dates in June 2026, June 2027, and June 2028, and specifies the exact tranche amounts and dates for those restrictions.

STERIS plc (STE) insider action by Renato Tamaro: The reporting person exercised an employee stock option to acquire 3,204 ordinary shares at a $147.05 per-share exercise price on 08/20/2025, then sold 3,204 shares the same day at a weighted average price of $249.24 per share. The exercise increased beneficial ownership to 10,425 shares before the sale, and after the sale the reporting person beneficially owns 7,221 ordinary shares. The filing notes 1,561 of the shares are subject to vesting restrictions with a specified lapse schedule. The option was awarded May 31, 2019 and is fully vested.

STERIS plc reports a Form 144 notice for the proposed sale of 3,204 ordinary shares via Charles Schwab & Co., Inc. on 08/20/2025 with an aggregate market value of $798,560.00 and 98,490,606 shares outstanding. The shares were acquired on 08/20/2025 through an employee stock option exercise with a broker-facilitated cashless exercise and payment. The filer certifies no undisclosed material adverse information about the issuer.

Richard C. Breeden, a director of STERIS plc (STE), reported an acquisition on 08/13/2025 of 4,110 ordinary shares via the exercise of a fully vested director stock option with an exercise price of $64.05 per share. After the transaction he beneficially owned 36,664 shares directly and 27,242 shares indirectly through affiliated entities, with certain indirect holdings described as interests in Breeden-managed funds and partnerships. The option is associated with terms originating from STERIS's 2019 redomiciliation and is exercisable with an indicated date of 08/31/2025. The Form 4 was signed on 08/15/2025.

Mohsen Sohi, a director of STERIS plc (STE), reported multiple equity transactions in August 2025. On 08/11/2025 the filings show a sale of 4,110 ordinary shares at a weighted average price of $241.96 per share and a related entry reflecting 4,110 ordinary shares associated with a $64.05 price. After the reported transactions, the form lists 22,361 ordinary shares beneficially owned directly by the reporting person.

Separately, on 08/08/2025 the reporting person received equity awards: a nonqualified director stock option to purchase 2,226 ordinary shares at an exercise price of $242.85 (described as fully vested and exercisable immediately), plus career restricted stock units of 772 and 506 ordinary shares. The filing notes the 506 RSUs were issued in lieu of $123,000 in fees and that career RSUs generally settle in ordinary shares six months after cessation of board service. An additional option to purchase 4,110 ordinary shares at $64.05 (fully vested) is also disclosed.

Louis Shapiro, a director of STERIS plc (STE), received a grant of 975 Career Restricted Stock Units on 08/08/2025, reported on Form 4. The RSUs are fully vested immediately and represent the right to receive one ordinary share each. Settlement is deferred until six months after the director ceases Board service. The Form 4 was filed as a single reporting person filing and signed by an authorized representative on 08/12/2025. No cash price was paid for these units and they are reported as direct beneficial ownership of 975 ordinary shares upon settlement.